Close

Registration is free and only takes a moment. If you have already registered, please log in now.

Create Account
Forgot your password?
Log In
  • Links
  • Publisher Full Text
  • Authors
  • Crunkhorn S
  • MESH
  • Antitubercular Agents
  • Clinical Trials, Phase II as Topic
  • Drug Design
  • Humans
  • Medication Adherence
  • Mycobacterium tuberculosis
  • Nitroimidazoles
  • Oxazoles
  • Tuberculosis, Multidrug-Resistant

Unbound MEDLINE

Trial watch: Novel antimicrobial fights TB resistance.

Links

  • Publisher Full Text

    • Authors

    Crunkhorn S

    Source

    Nature reviews. Drug discovery 11:8 2012 Aug pg 590

    MeSH

    Antitubercular Agents
    Clinical Trials, Phase II as Topic
    Drug Design
    Humans
    Medication Adherence
    Mycobacterium tuberculosis
    Nitroimidazoles
    Oxazoles
    Tuberculosis, Multidrug-Resistant

    Pub Type(s)

    News

    Language

    eng

    PubMed ID

    22814418

    Related Citations

    • Advances in the treatment of tuberculosis.
    • Microbiology. TB--a new target, a new drug.
    • Infectious disease. Approval of novel TB drug celebrated--with restraint.
    • Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain.
    • Resistance to anti-tuberculosis medications in the Horn of Africa.
    • [Multidrug-resistant tuberculosis].
    • Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives.
    • Resistance patterns of multidrug-resistant tuberculosis in Western Province, Papua New Guinea.
    More
    unbound logo
    • Home »
    • Contact Us »
    • Help »
    • Privacy / Disclaimer »
    • Terms of Service »
    • Log In »
    • twitter
    • facebook
    © 2000–2013 Unbound Medicine, Inc. All rights reserved